Eisai extends Belviq rights to most countries worldwide
This article was originally published in Scrip
Executive Summary
Eisai has expanded its marketing and supply agreement for Arena Pharmaceuticals' obesity drug Belviq (lorcaserin), paying $60m upfront to acquire rights in most territories worldwide on top of the 21 North and South American countries covered by the two firms' existing alliance for the product.